Now Available: Video Podcasts of MSK Report's Meeting Coverage

With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.

MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.

ACR 2007: Visit Musculoskeletal Report's dedicated ACR 2007 page for complete coverage of the American College of Rheumatology's 71st Annual Scientific Meeting, including press conference videos and interviews with presenters.

ACR 2007: Certolizumab Induces Faster Responses in RA
Thirty percent of RA patients treated with certolizumab plus MTX reached ACR20 within the first week of treatment; 50% reached ACR20 within 2 weeks...

ACR 2007: TNF-Blocker Plus MTX Slashes Heart Risk in RA
Combination therapy with a TNF-inhibitor plus MTX slashes heart attack risk by 80% in rheumatoid arthritis (RA) patients...

ACR 2007: Early Surgery Trumps Steroids for Long-Term Outcomes in Carpal Tunnel Syndrome
Decompression surgery is three times more effective than local corticosteroid injections for primary carpal syndrome...

BioPharm Business: Abbott's Humira Receives Positive Opinion From EMEA for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott Laboratories announced that the Committee for Medicinal Products for Human Use (CHMP), granted Abbott a positive opinion recommending approval of Humira (adalimumab) for the treatment of moderate-to-severe plaque psoriasis...

BioPharm Business: Novartis Says Health Regulators in UK and Germany Suspend Marketing and Sale of Prexige Pending Outcome of European Regulatory Review
Novartis Pharmaceuticals AG announced that health regulators in the UK and Germany have suspended the marketing and sale of Prexige (lumiracoxib), a COX-2 inhibitor for patients with osteoarthritic pain, following a review of the drug's benefit/risk profile...

BioPharm Business: UCB Reports that the Committee for Medicinal Products for Human Use has Denied Market Authorization in the EU for Cimzia to Treat Crohn's Disease; UCB to Appeal
UCB Pharma SA announced that it has been informed by the European Medicines Agency that the Committee for Medicinal Products for Human Use has rejected a marketing authorization in the EU for Cimzia (certolizumab pegol) for reducing signs and symptoms and maintaining clinical response in patients with severe, active Crohn's disease...

To remove your e-mail address from our mailing list, please reply to this e-mail with "unsubscribe" in the subject line. For questions and comments regarding this newsletter please contact .